Alfa Wassermann

In 2008, Norgine acquired the commercialisation rights from Alfa Wassermann for rifaximin-α for gastrointestinal indications such as traveller’s diarrhoea and hepatic encephalopathy.

Norgine currently holds marketing rights for XIFAXAN® 550mg (known as TARGAXAN® 550 in the UK and some other markets) in Australia, Belgium, Denmark, Finland, Germany, Luxembourg, Netherlands, New Zealand, Norway, Republic of Ireland, Sweden, United Kingdom and Switzerland. Norgine and Alfa Wassermann co-promote the product under the TIXTAR® brand name in France.